INSILICO

Insilico Medicine opened higher but trimmed gains in the morning session, reaching an intraday high of HK$47.92 before pulling back to HK$47.46, up about 7.1% from the opening of HK$44.32 but below the session peak. The rally was driven by a strategic BioAI partnership with Tencent Health, adding to a string of recent collaboration announcements with Boryung, CMS, and others. However, financials remain under pressure: Q4 2025 net loss widened to ~HK$1.296 billion, a year-over-year decline of over 1,228%, with EPS of -HK$16.18 and a net margin of -1,157%. Revenue grew only 10.3% YoY. At HK$47.4, the stock is still 41.4% below its 52-week high of HK$80.9, yet above its 20-day MA of HK$42.27 and up 26.1% YTD, suggesting investor optimism around partnerships is partially offsetting weak fundamentals.

3696.HK (Innoscience) fell sharply in the morning session, opening at 44.980 and hitting a session low of 42.300, closing down 5.28% from the previous close of 44.580. The decline was driven by the company's continued deterioration in fundamentals, with net profit plunging over 1,100% year-over-year for two consecutive quarters; Q4 2025 net loss reached 1.296 billion HKD and EPS was -16.1762, while ROE dropped to -147.38%. The stock price is now 47.71% below its 52-week high of 80.900, though it still holds a YTD gain of 12.56%. Currently at 42.300, it trades slightly above the 20-day MA (41.951) but well below the 60-day MA (47.29), suggesting short-term support but medium-term weakness. However, recent partnership announcements—including deals with Tencent Health and Boryung—may provide some counterbalance to the negative sentiment.

Yingxi Smart opened strongly in the morning session, climbing from 43.76 HKD to 45.46 HKD, closing up 5.41% on sustained AI drug discovery hype and value reassessment of its Pharma.AI platform. Q4 2025 revenue grew 10.29% YoY to 112 million HKD, but net loss widened 12.28x YoY to -1.296 billion HKD, with EPS at -16.18 HKD, largely due to R&D and share-based expenses; the stock at 45.62 HKD has reclaimed its 20-day MA (41.88 HKD) but remains 43.61% below the 52-week high of 80.90 HKD, with YTD gain of 21.39% and PB of 7.48x though still in a low historical range. However, the company remains loss-making with rapid cash burn, making the trajectory of loss narrowing the key watchpoint.

InSilico Medicine opened at HK$48.82 in the morning session but quickly fell to close at HK$46.60, down 4.94% from the previous close of HK$49.02, following a spike-and-reversal pattern. The company recently deepened its CNS drug development partnership with China Medical System and announced a strategic alliance with Bora Pharmaceuticals for AI-driven drug discovery. InSilico also forecasted a net profit of USD 33.5-39.5 million for the first half of 2026, signaling a potential turnaround to profitability. However, the stock still trades 42.4% below its 52-week high of HK$80.9 and below its 60-day moving average of HK$48.292, indicating lingering concerns about the sustainability of its profit recovery and the progress of its AI drug pipeline.

Huidong Intelligent opened the morning session at 46.74 HKD, slightly above the prior close of 46.32 HKD, then dipped to an intraday low of 46.72 HKD before launching a strong rally to a high of 51.75 HKD and closing at 50.95 HKD, a 9.99% gain, with turnover of approximately 757 million HKD and a turnover rate of 2.63%. The stock has surged 35.44% YTD since its listing, and while the current price of 50.9 HKD remains 37.08% below its 52-week high of 80.9 HKD, it has recovered above both the MA20 (40.24 HKD) and MA60 (48.87 HKD), indicating robust buying momentum at lower levels. In Q4 2025, revenue grew 10.29% year-on-year to about 112 million HKD, but net loss widened 1228.18% to 1.296 billion HKD, with an EPS of -16.18 HKD, reflecting persistent fundamental pressure; however, the operating loss narrowed 5.42% year-on-year, suggesting initial cost-control gains.